INVO Bioscience (NASDAQ:INVO – Get Rating) and Glaukos (NYSE:GKOS – Get Rating) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.
Earnings & Valuation
This table compares INVO Bioscience and Glaukos' revenue, earnings per share and valuation.
Get INVO Bioscience alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| INVO Bioscience | $4.16 million | 4.51 | -$6.66 million | N/A | N/A |
| Glaukos | $294.01 million | 9.18 | -$49.59 million | ($1.19) | -47.93 |
INVO Bioscience has higher earnings, but lower revenue than Glaukos.
Profitability
This table compares INVO Bioscience and Glaukos' net margins, return on equity and return on assets.| Net Margins | Return on Equity | Return on Assets | |
| INVO Bioscience | -222.62% | -165.97% | -92.06% |
| Glaukos | -19.35% | -13.82% | -7.73% |
Insider & Institutional Ownership
11.8% of INVO Bioscience shares are owned by institutional investors. Comparatively, 93.1% of Glaukos shares are owned by institutional investors. 10.4% of INVO Bioscience shares are owned by company insiders. Comparatively, 8.1% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
INVO Bioscience has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and price targets for INVO Bioscience and Glaukos, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| INVO Bioscience | 0 | 1 | 2 | 0 | 2.67 |
| Glaukos | 1 | 4 | 4 | 0 | 2.33 |
INVO Bioscience presently has a consensus target price of $2.50, suggesting a potential upside of 62.34%. Glaukos has a consensus target price of $57.38, suggesting a potential upside of 0.59%. Given INVO Bioscience's stronger consensus rating and higher possible upside, equities analysts clearly believe INVO Bioscience is more favorable than Glaukos.
Summary
Glaukos beats INVO Bioscience on 8 of the 12 factors compared between the two stocks.
About INVO Bioscience
(Get Rating)
INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.
About Glaukos
(Get Rating)
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Receive News & Ratings for INVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.